Prana Biotechnology Current Ratio 2010-2022 | ATHE

Prana Biotechnology current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Prana Biotechnology Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $0.03B $0.00B 7.07
2021-12-31 $0.03B $0.00B 11.92
2021-06-30 $0.03B $0.00B 10.92
2020-12-31 $0.03B $0.00B 12.29
2020-06-30 $0.01B $0.00B 3.62
2019-12-31 $0.01B $0.00B 4.44
2019-06-30 $0.01B $0.00B 5.98
2018-12-31 $0.01B $0.00B 4.37
2018-06-30 $0.01B $0.00B 7.06
2017-12-31 $0.02B $0.00B 12.12
2017-06-30 $0.02B $0.00B 15.99
2016-12-31 $0.02B $0.00B 10.66
2016-06-30 $0.03B $0.00B 14.27
2015-12-31 $0.03B $0.00B 16.41
2015-06-30 $0.04B $0.00B 15.36
2014-12-31 $0.03B $0.00B 12.09
2014-06-30 $0.04B $0.00B 10.54
2013-12-31 $0.02B $0.00B 5.16
2013-06-30 $0.02B $0.00B 5.48
2012-12-31 $0.01B $0.00B 3.81
2012-06-30 $0.01B $0.00B 4.23
2011-12-31 $0.01B $0.00B 3.64
2011-06-30 $0.01B $0.00B 4.31
2010-12-31 $0.00B $0.00B 3.25
2010-06-30 $0.01B $0.00B 4.48
2009-12-31 $0.01B $0.00B 9.53
2009-06-30 $0.00B $0.00B 5.68
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.003B
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00